Abstract
511MO A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced non-small cell lung cancer (NSCLC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have